Limiting numbers of G156A O6-methylguanine-DNA methyltransferase- transduced marrow progenitors repopulate nonmyeloablated mice after drug selection

Blood

Volumn 95, Issue 10, 2000, Pages 3078-3084

  Davis, Brian M ^b   Koç, Omer N ^b   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; 6 O BENZYLGUANINE DNA METHYLTRANSFERASE; CARMUSTINE; DNA METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CELL SELECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENCY; DRUG SPECIFICITY; ENZYME BINDING; GENE THERAPY; HEMATOPOIETIC STEM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034657950     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.10.3078     Document Type: Article

References (31)

1. Kohn D, Weinberg K, Nolta J, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1995;1:1017.
2. Barranger J, Rice E, Dunigan J, et al. Gaucher's disease: studies of gene transfer to haematopoietic cells. Baillier Clin Haematol. 1997;10:765.
3. Malech H, Maples P, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94:12,133.
4. Dunbar C, Kohn D, Schiffmann R , et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther. 1998;9:2629.
5. Sorrentino B, Brandt S, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992;257:99.
6. Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug-resistance gene into live mice. Proc Natl Acad Sci U S A. 1992;89:9676.
7. Corey C, DeSilva A, Holland C, Williams D. Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood. 1990;75:337.
8. Allay J, Persons D, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136.
9. Allay J, Davis B, Gerson S. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp Hematol. 1997;25:1069.
10. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res. 1992;52:6052.
11. 6-benzylguanine. Biochemistry. 1993;32:11,998.
12. 1-bis(2-chloroethyl)-N-nitrosourea. Cancer Res. 19B2;42: 3102.
13. 6-benzylguanine plus BCNU. Blood. 1996;88:1649.
14. 6-benzylguanine plus BCNU. Proc Natl Acad Sci U S A. 1996;93:14,088.
15. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1997;57:5093.
16. 6-alkylguanine-DNA alkyltransferase. Science. 1993;259:219-222.
17. 6-methylguanine in DNA. J Mol Biol. 1990;213:739-747.
18. Stewart F, Crittenden R, Lowry P, Pearson-White S, Quesenberry P. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 1993; 81:2566.
19. Ramshaw H, Rao S, Crittenden R, Peters S, Weier H, Quesenberry P. Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. Blood. 1995;86:924.
20. Peters S, Kittler E, Ramshaw H, Quesenberry P. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol. 1995; 23:461.
21. Davis B, Gerson S. Comparison of three retroviral promoters for in vivo expression of the drug-resistance gene ΔMGMT in murine hematopoietic cells and tissues [abstract]. Am Soc Gene Therapy. 1998;1:90a.
22. Rao S, Peters S, Crittenden R, Stewart F, Ramshaw H, Quesenberry P. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997;25:114-121.
23. Szilvassy S, Humphries R, Lansdorp P, Eaves A, Eaves C. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci U S A. 1990;87:8736.
24. Miller D, Adam M, Miller A. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection [published correction appears in Mol Cell Biol. 1992;12:433]. Mol Cell Biol. 1990;10:4239.
25. Blau C, Neff T, Papayannopoulou T. The hematologic effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Therapy. 1996;7:2069.
26. Bertolini F, Battaglia M, Lanza A, et al. Multilineage long-term engraftment potential of drug resistant hematopoietic progenitors. Blood. 1997; 90:3027.
27. Blau C, Neff T, Papayannopoulou T. Cytokine prestimulation as a gene therapy strategy: implications for using the MDR1 gene as a dominant selectable marker. Blood. 1997;89:146.
28. 6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998;16:1803.
29. 6-alkylguanine-DNA alkyltranslerase in tumor tissue: a phase I pharmacokinetic/pharmacodynamic study [abstract]. Proc Am Soc Clin Oncol. 1998;17:212a.
30. 6-benzylguanine and BCNU and allows intensive therapy of BCNU resistant human colon cancer xenografts. Hum Gene Ther. 1999;10:1021.
31. 6-benzylguanine and BCNU therapy of advanced solid tumors. Case Western Reserve U Clin Protocol, 1998;2Y97.